Genetic Testing and Screening

Home/Tools of the Trade/Genetic Testing and Screening

Making Sense of the Diagnostic Tests During Pregnancy

Guiding you through the pregnancy screening and testing process

Although both screening and testing for genetic disorders is offered to all pregnant women during the course of her prenatal care, there are women who are considered to be at a higher risk for having a baby with a genetic disorder. Many decisions regarding screenings are based on her family history.

Screening vs testing

There is a difference between screening for genetic disorders and testing for genetic disorders.

The purpose of screening is to determine which individuals may have a higher risk factor for the disease or disorder. Screening does not determine a diagnosis. It is simply a method to identify those that might have a specific condition from those that most likely do not. Screenings are not always accurate. The results may show that there is an increased chance of something being abnormal, when it isn’t. The results may also indicate that there is nothing abnormal, when there actually is. These types of errors are referred to as “false-positive,” and “false-negative,” results.1 The results of a screening will be used to help you and your physician decide on the next step. The American College of Obstetricians and Gynecologists (ACOG) recommends that all pregnant women are offered screening, as well as testing, even if there are no risk factors identified.2

Based on the results of a screening, your physician will discuss the options for additional testing. Testing, unlike screening, will determine of the condition being tested for is present or not.

Screenings for genetic disorders

Nuchal Translucency Ultrasound Screening for Down Syndrome

The Nuchal translucency ultrasound is performed between the 10th and 12th week of gestation. An ultrasound is done in which the nuchal fold (a space that is filled with fluid located behind baby’s neck). A nuchal fold that is greater than 3 millimeters means that there is an increased risk of Down syndrome. An increase in thickness may also indicate the presence of other genetic disorders, such as heart defects and diaphragmatic hernia. 

Nuchal Translucency Ultrasound

Nuchal Translucency Ultrasound

Maternal Serum Alpha Fetoprotein

A Maternal Serum Alpha Fetoprotein screening involves collecting a sample of a pregnant woman’s blood. This is done during the 15th and 18th week of pregnancy. It is a screening tool for the possibility of a baby having a genetic disorder, such as Spina Bifida, or Down Syndrome.


This screening is recommended to be performed between the 10th and 14th week of pregnancy. A blood sample is taken and the level (amount) of PAPP-A (pregnancy-associated plasma protein A), and hCG (human chorionic gonadotropin) present in the bloodstream is measured. It is then compared to the woman’s age, weight, and gestational age (how far along she is in pregnancy). A lower PAPP-A level, and a higher hCG level could indicate a higher risk for Down Syndrome.

Integrated (Sequential) Second Trimester Screening: Screening for Down Syndrome (Trisomy 21), Trisomy 18, and Neural Tube Defects.

Integrated (also known as Sequential) screening includes two blood tests and an ultrasound. The first blood test is recommended to be drawn between the 11th and 13th week of pregnancy. The first blood test involves PAPP-A screening. For the second blood test, a quad screen is performed.


The second blood test is recommended to be drawn between week 15 and week 18 of pregnancy, but it may be performed up to week 21 of pregnancy.

Diagnostic tests for genetic disorders

Chorionic villus sampling

Chorionic villus sampling is performed during the 10th and 14th week of pregnancy. During this procedure, the physician collects a small amount of tissue from the placenta, either through the cervix (trans-cervically), or through the abdomen (trans-abdominally). The small amount of placental tissue is sent to the lab and tested for what is called aneuploidy (chromosome abnormalities). It is also possible to determine the sex of the baby. The placental tissue may also be tested for Tay-Sachs Disease, Huntington Disease, Hemophilia A, and Cystic Fibrosis.


An Amniocentesis is performed during the 16th and 18th week of pregnancy. During this procedure, your physician, or a Maternal Fetal Medicine Specialist (a doctor who specializes in high-risk pregnancies), inserts a needle into the abdomen, using an ultrasound machine is used to make sure that the needle goes into the right spot. A small amount of amniotic fluid will be withdrawn. The amniotic fluid will be tested to determine whether or not a fetus has  Down syndrome, Trisomy 18, It can also be used to test for Cystic Fibrosis, Hemophilia A, Huntington Disease, Tay-Sachs Disease, and open neural tube defects, such as Spina Bifida.

More in-depth information here:

A Quick Guide to Pregnancy Week by WeekDealing with Preterm Labor
Changes in Your Body During PregnancyInduction of Labor
Finding Out Your Due DateGenetic Testing and Screening
Keeping Yourself and Your Baby HealthyMonitoring Fetal Movement During Your Pregnancy
The First Prenatal VisitWhat Does the EFM do?
What You Should Know About Morning SicknessThe Benefits of Folic Acid

Compassionate representation for families

At Crandall & Pera Law, our Ohio and Kentucky birth injury lawyers offer free case evaluation. You are welcome to call 877-955-0020 or fill out our contact form to schedule an appointment at one of our Kentucky office locations in Lexington and Louisville, and our Ohio locations in Cleveland, Columbus, Chagrin Falls, Cincinnati, and Chesterland.

  1. Bellver, J., Casanova, C., Garrido, N., Lara, C., Remohi, J., Pellicer, A., &   Serra, V. (2013). Additive effect of factors related to assisted conception on the reduction of maternal serum pregnancy-associated plasma protein A concentrations and the increased false-positive rates in first-trimester Down syndrome screening. Fertility and Sterility, 100(5), 1314-1320.e3. doi: 10.1016/j.fertnstert.2013.06.045
  2. Wilson, K., Czerwinski, J., Hoskovec, J., Noblin, S., Sullivan, C, Harbison, A., Campion, M., Devary, K., Devers, P., Singletary, C. (2012). NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy. Journal of Genetic Counseling, 22(1), 4-15. doi: 10.1007/s10897-012-9545-3